A detailed history of Vise Technologies, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Vise Technologies, Inc. holds 20,445 shares of ABBV stock, worth $3.62 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares
20,445
Previous 17,322 18.03%
Holding current value
$3.62 Million
Previous $2.97 Million 35.88%
% of portfolio
0.52%
Previous 0.53%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $511,672 - $622,507
3,123 Added 18.03%
20,445 $4.04 Million
Q2 2024

Aug 01, 2024

BUY
$154.79 - $180.76 $254,010 - $296,627
1,641 Added 10.46%
17,322 $2.97 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $54,978 - $62,642
-344 Reduced 2.15%
15,681 $2.86 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $174,614 - $196,656
-1,269 Reduced 7.34%
16,025 $2.48 Million
Q3 2023

Oct 31, 2023

BUY
$133.59 - $154.65 $413,995 - $479,260
3,099 Added 21.83%
17,294 $2.58 Million
Q2 2023

Aug 08, 2023

SELL
$132.51 - $164.9 $130,522 - $162,426
-985 Reduced 6.49%
14,195 $1.91 Million
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $556,170 - $640,512
3,846 Added 33.93%
15,180 $2.42 Million
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $3,596 - $4,312
-26 Reduced 0.23%
11,334 $1.83 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $767,412 - $880,171
5,718 Added 101.35%
11,360 $1.53 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $387,950 - $493,212
2,819 Added 99.86%
5,642 $864,000
Q1 2022

Jun 08, 2022

BUY
$131.98 - $163.75 $372,579 - $462,266
2,823 New
2,823 $458,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Vise Technologies, Inc. Portfolio

Follow Vise Technologies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vise Technologies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vise Technologies, Inc. with notifications on news.